We’re proud to share that Apeloa Jiayuan successfully completed a U.S. FDA cGMP inspection in April 2025 with zero observations — no Form 483 issued.
The 5-day inspection covered 21 registered products across 8 workshops, highlighting our commitment to full compliance and quality excellence.
This marks the 19th U.S. FDA inspection across Apeloa’s manufacturing network, and the 6th at our Jiayuan site, enabling global clients in expediting the delivery of affordable medications.
